#USA #Los Angeles #biotechnology #Armata Pharmaceuticals #AP-SA02

Armata Pharmaceuticals Reports Financial and Clinical Updates for Q1 2025

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company listed on NYSE American under the symbol ARMP, has released its financial results for the first quarter of 2025, ending March 31. The company specializes in the development of high-purity, pathogen-specific bacteriophage therapeutics aimed at combating antibiotic-resistant infections.

Key Developments

During the first quarter, Armata made significant strides in its ongoing clinical trials, particularly the Phase 1b/2a diSArm study of the intravenous drug AP-SA02, developed to treat Staphylococcus aureus bacteremia. Topline results from this important study are anticipated in the first half of 2025.

In terms of funding, Armata has secured an additional $4.65 million through a non-dilutive award from the U.S. Department of Defense, which will support the ongoing clinical efforts for AP-SA02 and help facilitate a meeting with the U.S. Food and Drug Administration (FDA) concerning the next steps in the clinical trial process.

CEO Dr. Deborah Birx commented, "The first quarter was progressive for Armata, culminating in the completion of our third Phase 2 study. The data we expect to receive next will bolster our efforts toward potential pivotal trials and regulatory approval."

Financial Highlights

The financial results for Q1 2025 reflect both the challenges and opportunities facing the company:

• - Grant and Award Revenue: Armata reported revenue of $0.5 million, a decrease from $1.0 million in Q1 2024. This reflects the support for the AP-SA02 program's phase of development.
• - Research and Development: The R&D expenses amounted to approximately $5.4 million, down from $8.0 million during the same period in 2024, as the company focuses on essential clinical expenditures.
• - General and Administrative Costs: These rounded out to around $3.3 million, a slight increase compared to $3.2 million in the prior year, primarily driven by higher personnel costs.
• - Net Loss: Armata incurred a net loss of $6.5 million, significantly reduced from $25.0 million in the previous year, aided by a non-cash gain from changes in the fair value of its convertible loans.
• - Cash Reserves: As of the end of March 2025, Armata had approximately $11.7 million in unrestricted cash, an increase from $9.3 million at the end of the previous year.

Continuing Commitment to Phage Therapeutics

Armata remains dedicated to pioneering bacteriophage therapy, which employs naturally occurring viruses that specifically target and kill bacteria. The company emphasizes rigorous randomized controlled clinical trials that are necessary for potential regulatory approval.

At the recent 7th Annual Bacteriophage Therapy Summit in Boston, Armata showcased advancements in bacteriophage science, enhancing knowledge sharing and collaboration within the biopharmaceutical community.

Dr. Birx concluded, "Our focus remains steadfast on evaluating the potential of phage-based therapeutics through well-structured trials that can pave the way for regulatory pathways and market introduction. We are exceedingly pleased with the momentum that we have developed thus far."

In summary, Armata Pharmaceuticals is navigating through its clinical trials and financial landscape determined to address the urgent need for effective treatments against antibiotic-resistant infections through innovative bacteriophage therapies. The results shared today underscore the company’s commitment to advancing healthcare while also managing operational efficiencies during this critical period.